Genitourinary Syndrome of Menopause (GSM)Early Phase 1NCT07160127
A Clinical Study of Chinese Herbal Formula TJAOA103 in Treating Genitourinary Syndrome of Menopause
A Early Phase 1 study testing TJAOA103 in people with Genitourinary Syndrome of Menopause (GSM), run by Tongji Hospital at 1 site in China.
Trial summary
The goal of this clinical trial is to learn if Chinese herbal formula TJAOA103 works to treat genitourinary syndrome of menopause (GSM). It will also learn about the safety of TJAOA103. The main questions it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 45 to 70 years, women only
- Conditions the study is for
- Genitourinary Syndrome of Menopause (GSM)
- What is being tested?
- TJAOA103
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 113 participants
- Where
- 1 siteChina
- Study dates
- 15 Sep 2025to 15 Sep 2027
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 70 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Females aged 45-70 years during the menopausal transition or postmenopausal period.
- Presence of at least one moderate-to-severe (score ≥ 2) symptom of GSM, including vulvovaginal dryness, or vulvovaginal itching/irritation, or vulvovaginal burning/pain, or dyspareunia, or dysuria/urinary frequency/urgency.
- Willing to participate in this trial and sign a written informed consent form.
Who cannot join
- Acute or recurrent genitourinary infection.
- Acute or chronic dermatosis of the vulva or vagina.
- A grade 3 or higher degree of prolapse according to the Pelvic Organ Prolapse Quantification (POP-Q) system.
- Unexplained abnormal uterine bleeding.
- Ovarian/adnexal mass ≥ 4 cm, or adenomyosis, or adenomyoma/uterine myoma ≥ 4 cm.
- Breast Imaging Reporting and Data System (BI-RADS) classification of breast ultrasound ≥ 4.
Show all 15Show fewer
- Presence of precancerous lesions or diagnosed malignancy.
- Liver or kidney function indicators (ALT, AST, Urea, Cr) exceeding the upper limits of reference ranges upon repeated testing.
- Severe primary diseases of the nervous, circulatory, respiratory, digestive, urinary or hematopoietic systems; or mental diseases;
- Known allergy to any specific ingredient of the trial drugs.
- Systemic hormone therapy within the past 2 months.
- Application of vaginal moisturizers, lubricants, hormone preparations, or alternative therapies for GSM within the past month.
- Current participation in another clinical trial or participation in another trial within the past month.
- Unwillingness to discontinue the use of moisturizers, lubricants, or any form of hormonal drugs during the trial.
- Other conditions deemed unsuitable for participation by the investigators.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan
Jinjin Zhang, Associate Professor, +8613469995233, jinjinzhang@tjh.tjmu.edu.cn
Yueyue Gao, 2024tj0062@hust.edu.cn
About this study
Official title: The Efficacy and Safety of Chinese Herbal Formula TJAOA103 for the Treatment of Genitourinary Syndrome of Menopause: A Prospective and Single-Arm Study
The goal of this clinical trial is to learn if Chinese herbal formula TJAOA103 works to treat genitourinary syndrome of menopause (GSM). It will also learn about the safety of TJAOA103. The main questions it aims to answer are:
- Does TJAOA103 alleviate the symptoms of GSM in participants or have any other benefits?
- What medical problems do participants have when taking TJAOA103? Researchers will conduct a pre-post comparison to see if TJAOA103 works to treat GSM.
Participants will:
- Take TJAOA103 twice daily for 4 to 12 weeks.
- Complete the tests and/or questionnaires on schedule through online follow-up or outpatient visits.
- Record their use of TJAOA103 and any adverse events.
Read the detailed description
Genitourinary syndrome of menopause (GSM) refers to a collection of symptoms and signs such as atrophy of the genital and urinary tracts and sexual dysfunction in women during the menopausal transition and postmenopausal period due to the decline in estrogen and other sex hormone levels. The primary pathogenesis is rooted in ovarian aging. GSM not only causes persistent discomfort and increases the risk of infections but also significantly impairs sexual function and self-esteem in middle-aged and older women. Furthermore, the failure of ovarian hormone function will markedly elevate the risk of aging-related diseases such as cardiovascular events, Alzheimer's disease, and osteoporosis in these patients, shortening their healthspan and increasing all-cause mortality. Therefore, timely intervention for GSM is crucial.
At present, vaginal moisturizers, lubricants, and vaginal estrogen preparations are commonly used in clinical practice to alleviate the symptoms of GSM. Vaginal moisturizers and lubricants help protect the vaginal epithelium and maintain an acidic vaginal environment, but may cause vaginal burning, infections, or allergic reactions. Vaginal estrogen preparations exert their effects on estrogen receptors within the genitourinary system, yet the long-term safety remains uncertain. Ospemifene, a selective estrogen receptor modulator, is another treatment option; however, its weak estrogenic effects may pose risks of thrombosis or endometrial thickening with prolonged use. In addition, laser therapy has also been employed for GSM, but carries potential safety risks including vaginal burns, scarring, and chronic pain.
Traditional Chinese medicine (TCM) possesses distinctive advantages in anti-aging strategies, addressing both symptoms and root causes with commendable safety profiles, thereby rendering it particularly appropriate for middle-aged and elderly populations. Numerous studies have demonstrated the effectiveness of TCM in the management of GSM-related conditions, such as postmenopausal vaginal dryness, atrophic vaginitis, and menopausal urethral syndrome. However, due to the limited understanding of the disease, existing TCM prescriptions have lacked specificity for GSM and often rely on empirical combinations without solid scientific foundation. To solve this problem, we have invented a novel TCM formula, Tongji Anti-Ovarian Aging 103 (TJAOA103). First, we performed an extensive literature retrieval to collect TCM prescriptions effective in alleviating GSM-associated symptoms. Using the TCM Inheritance Support System and the TCM Systems Pharmacology Database and Analysis Platform, we screened out a variety of candidate Chinese herbs and combinations with potential therapeutic effects on GSM, based on its pathogenesis. Then, a panel of senior experts in gynecology, TCM, and pharmacy thoroughly discussed the pharmacological actions, synergistic effects, contraindications, and dosages of these herbs, and developed the initial formula of TJAOA103. Subsequently, we utilized multiple models to verify the safety and effectiveness of TJAOA103, and further optimized the formulation.
This is a prospective, single-arm clinical study designed to evaluate the safety and efficacy of the TCM formula TJAOA103 in women diagnosed with GSM. Using a pre-post analysis, we will assess the improvements in clinical symptoms, signs, sexual function, genitourinary health, and quality of life in participants with GSM following TJAOA103 administration to provide a safe and reliable novel therapeutic strategy for this population.
- Being tested
- TJAOA103
- Keywords
- Genitourinary Syndrome of Menopause, Traditional Chinise Medicine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TJAOA103Drug
Once enrolled, participants will be administered TJAOA103 for 4 to 12 weeks. TJAOA103 should be taken orally twice a day, one sack each time. Dissolve it in about 200 mL of warm water and drink it all. Participants can take it half an hour before breakfast in the morning and half an hour before bedtime in the evening.
| Study group | Role | What they receive |
|---|---|---|
| TJAOA103 | Experimental | Once enrolled, participants will be administered TJAOA103 for 4 to 12 weeks. Receives: Drug: TJAOA103 |
What is being measured
The primary outcome is the main question the study is designed to answer.
severity of the most bothersome symptom (MBS)
The MBS is derived from a selected list of common GSM symptoms, including vulvovaginal dryness, vulvovaginal itching/irritation, vulvovaginal burning/pain, dyspareunia, and dysuria/urinary frequency/urgency. At baseline, participants will be instructed to rate the severity of each symptom as absent (0), mild (1), moderate (2), or severe (3). They will then be asked to select a single MBS among those symptoms they classify as moderate or severe (i.e., a score ≥ 2). The MBS will be tracked through to the end of treatment, and the changes in its severity will be used to assess symptomatic improvement.
Measured: From enrollment to the end of treatment at 4 or 12 weeks
Secondary outcomes (8)
total score of GSM symptoms
The total score, which ranges from 2 to 15, is the sum of the five individual symptom scores. The higher the score, the more severe the GSM symptoms are.
Measured: From enrollment to the end of treatment at 4 or 12 weeks
score for a specific GSM symptom
The self-assessed severity score for a specific GSM symptom is assigned as 0, 1, 2, or 3 points, corresponding respectively to absent, mild, moderate, and severe.
Measured: From enrollment to the end of treatment at 4 or 12 weeks
Vaginal Health Index Score (VHIS)
The total score of VHIS ranges from 5 to 25. The lower the score, the worse the vaginal health condition.
Measured: From enrollment to the end of treatment at 4 or 12 weeks
vaginal pH
A pH level of 4.6 or above indicates vaginal atrophy.
Measured: From enrollment to the end of treatment at 4 or 12 weeks
Female Sexual Function Index-6 (FSFI-6)
The score of FSFI-6 ranges from 2 to 30. A score of 19 or less is considered an indication of female sexual dysfunction.
Measured: From enrollment to the end of treatment at 4 or 12 weeks
Overactive Bladder Syndrome Score (OABSS)
The total OABSS score ranges from 0 to 15. When the score for urinary urgency is 2 or higher, and the total OABSS score is 3 or higher, a diagnosis of overactive bladder syndrome (OAB) can be made. Generally, a total score of 3 to 5 indicates mild OAB, 6 to 11 indicates moderate OAB, and ≥12 indicates severe OAB.
Measured: From enrollment to the end of treatment at 4 or 12 weeks
score of International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)
The score of ICIQ-SF ranges from 0 to 21. A higher score indicates more severe urinary incontinence symptoms and a greater impact on the patient's daily life.
Measured: From enrollment to the end of treatment at 4 or 12 weeks
score of Menopause-Specific Quality of Life Questionnaire (MENQOL)
The MENQOL consists of 4 domains, namely vasomotor, psychosocial, physical, and sexual functioning, with a total of 29 items. Participants are instructed to evaluate the existence and degree of bother from their symptoms using a 7-point Likert scale, where higher scores indicate a greater degree of bothersome symptoms. The score for each domain is calculated as the average score of its individual items. The total score is the mean of the four domain scores.
Measured: From enrollment to the end of treatment at 4 or 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2025
- Study start15 Sep 2025 (estimated)
- Primary completion15 Jun 2027 (estimated)
- Study completion15 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Genitourinary Syndrome of Menopause (GSM)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 113 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tongji Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jinjin Zhang, Tongji Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07160127
- Sponsor's protocol ID
- TJ-IRB202508073-GSM
- Status last verified
- Sep 2025
- First submitted
- 29 Aug 2025
- Last updated
- 17 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Efficacy and Safety of Chinese Herbal Formula TJAOA103 for the Treatment of Genitourinary Syndrome of Menopause: A Prospective and Single-Arm Study
- ClinicalTrials.gov ID
- NCT07160127
- Acronym / sponsor ID
- TJ-IRB202508073-GSM
- Keywords
- Genitourinary Syndrome of Menopause, Traditional Chinise Medicine
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 113 participants (estimated)
- Lead sponsor
- Tongji HospitalUniversity, hospital or other
- Study start
- 15 Sep 2025 (estimated)
- Primary completion
- 15 Jun 2027 (estimated)
- Study completion
- 15 Sep 2027 (estimated)
- First posted
- 8 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if Chinese herbal formula TJAOA103 works to treat genitourinary syndrome of menopause (GSM). It will also learn about the safety of TJAOA103. The main questions it aims to answer are:
- Does TJAOA103 alleviate the symptoms of GSM in participants or have any other benefits?
- What medical problems do participants have when taking TJAOA103? Researchers will conduct a pre-post comparison to see if TJAOA103 works to treat GSM.
Participants will:
- Take TJAOA103 twice daily for 4 to 12 weeks.
- Complete the tests and/or questionnaires on schedule through online follow-up or outpatient visits.
- Record their use of TJAOA103 and any adverse events.
Detailed description
Genitourinary syndrome of menopause (GSM) refers to a collection of symptoms and signs such as atrophy of the genital and urinary tracts and sexual dysfunction in women during the menopausal transition and postmenopausal period due to the decline in estrogen and other sex hormone levels. The primary pathogenesis is rooted in ovarian aging. GSM not only causes persistent discomfort and increases the risk of infections but also significantly impairs sexual function and self-esteem in middle-aged and older women. Furthermore, the failure of ovarian hormone function will markedly elevate the risk of aging-related diseases such as cardiovascular events, Alzheimer's disease, and osteoporosis in these patients, shortening their healthspan and increasing all-cause mortality. Therefore, timely intervention for GSM is crucial.
At present, vaginal moisturizers, lubricants, and vaginal estrogen preparations are commonly used in clinical practice to alleviate the symptoms of GSM. Vaginal moisturizers and lubricants help protect the vaginal epithelium and maintain an acidic vaginal environment, but may cause vaginal burning, infections, or allergic reactions. Vaginal estrogen preparations exert their effects on estrogen receptors within the genitourinary system, yet the long-term safety remains uncertain. Ospemifene, a selective estrogen receptor modulator, is another treatment option; however, its weak estrogenic effects may pose risks of thrombosis or endometrial thickening with prolonged use. In addition, laser therapy has also been employed for GSM, but carries potential safety risks including vaginal burns, scarring, and chronic pain.
Traditional Chinese medicine (TCM) possesses distinctive advantages in anti-aging strategies, addressing both symptoms and root causes with commendable safety profiles, thereby rendering it particularly appropriate for middle-aged and elderly populations. Numerous studies have demonstrated the effectiveness of TCM in the management of GSM-related conditions, such as postmenopausal vaginal dryness, atrophic vaginitis, and menopausal urethral syndrome. However, due to the limited understanding of the disease, existing TCM prescriptions have lacked specificity for GSM and often rely on empirical combinations without solid scientific foundation. To solve this problem, we have invented a novel TCM formula, Tongji Anti-Ovarian Aging 103 (TJAOA103). First, we performed an extensive literature retrieval to collect TCM prescriptions effective in alleviating GSM-associated symptoms. Using the TCM Inheritance Support System and the TCM Systems Pharmacology Database and Analysis Platform, we screened out a variety of candidate Chinese herbs and combinations with potential therapeutic effects on GSM, based on its pathogenesis. Then, a panel of senior experts in gynecology, TCM, and pharmacy thoroughly discussed the pharmacological actions, synergistic effects, contraindications, and dosages of these herbs, and developed the initial formula of TJAOA103. Subsequently, we utilized multiple models to verify the safety and effectiveness of TJAOA103, and further optimized the formulation.
This is a prospective, single-arm clinical study designed to evaluate the safety and efficacy of the TCM formula TJAOA103 in women diagnosed with GSM. Using a pre-post analysis, we will assess the improvements in clinical symptoms, signs, sexual function, genitourinary health, and quality of life in participants with GSM following TJAOA103 administration to provide a safe and reliable novel therapeutic strategy for this population.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| TJAOA103 | Experimental | Drug: TJAOA103Once enrolled, participants will be administered TJAOA103 for 4 to 12 weeks. |
Who may qualify
- Ages
- 45 to 70 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Females aged 45-70 years during the menopausal transition or postmenopausal period.
- Presence of at least one moderate-to-severe (score ≥ 2) symptom of GSM, including vulvovaginal dryness, or vulvovaginal itching/irritation, or vulvovaginal burning/pain, or dyspareunia, or dysuria/urinary frequency/urgency.
- Willing to participate in this trial and sign a written informed consent form.
Key exclusion criteria (15 listed)
- Acute or recurrent genitourinary infection.
- Acute or chronic dermatosis of the vulva or vagina.
- A grade 3 or higher degree of prolapse according to the Pelvic Organ Prolapse Quantification (POP-Q) system.
- Unexplained abnormal uterine bleeding.
- Ovarian/adnexal mass ≥ 4 cm, or adenomyosis, or adenomyoma/uterine myoma ≥ 4 cm.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TJAOA103Once enrolled, participants will be administered TJAOA103 for 4 to 12 weeks. TJAOA103 should be taken orally twice a day, one sack each time. Dissolve it in about 200 mL of warm water and drink it all. Participants can take it half an hour before breakfast in the morning and half an hour before bedtime in the evening. | Drug | TJAOA103 |
Primary outcome
severity of the most bothersome symptom (MBS)
Time frame: From enrollment to the end of treatment at 4 or 12 weeks
The MBS is derived from a selected list of common GSM symptoms, including vulvovaginal dryness, vulvovaginal itching/irritation, vulvovaginal burning/pain, dyspareunia, and dysuria/urinary frequency/urgency. At baseline, participants will be instructed to rate the severity of each symptom as absent (0), mild (1), moderate (2), or severe (3). They will then be asked to select a single MBS among those symptoms they classify as moderate or severe (i.e., a score ≥ 2). The MBS will be tracked through to the end of treatment, and the changes in its severity will be used to assess symptomatic improvement.
8 secondary outcomes
total score of GSM symptoms
Time frame: From enrollment to the end of treatment at 4 or 12 weeks
score for a specific GSM symptom
Time frame: From enrollment to the end of treatment at 4 or 12 weeks
Vaginal Health Index Score (VHIS)
Time frame: From enrollment to the end of treatment at 4 or 12 weeks
vaginal pH
Time frame: From enrollment to the end of treatment at 4 or 12 weeks
Female Sexual Function Index-6 (FSFI-6)
Time frame: From enrollment to the end of treatment at 4 or 12 weeks
Overactive Bladder Syndrome Score (OABSS)
Time frame: From enrollment to the end of treatment at 4 or 12 weeks
score of International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)
Time frame: From enrollment to the end of treatment at 4 or 12 weeks
score of Menopause-Specific Quality of Life Questionnaire (MENQOL)
Time frame: From enrollment to the end of treatment at 4 or 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2025.
Related trials for Genitourinary Syndrome of Menopause (GSM)
Not yet recruitingObservational study
Retrospective Cohort Study of Symptoms and Quality of Life in Women With Genitourinary Syndrome of Menopause.
Vulvar Atrophy, Vulvovaginal Signs and Symptoms
Not yet recruitingPhase 4
Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV
Menopausal Complaints, Vaginal Atrophy
Not yet recruiting
Photobiomodulation for Vaginal Dysfunctions: Home-Based vs Outpatient Treatment
Genitourinary Syndrome of Menopause (GSM), Bacterial Vaginosis
RecruitingObservational study
Determining the Extent of the Genitourinary Syndrome of Menopause Burden in Breast Cancer Survivors
Genitourinary Syndrome of Menopause (GSM), Breast Cancer
Recruiting
Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs.
Vulvar Atrophy, Vulvovaginal Signs and Symptoms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing TJAOA103 in people with Genitourinary Syndrome of Menopause (GSM), run by Tongji Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jinjin Zhang, Associate Professor (+8613469995233, jinjinzhang@tjh.tjmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
severity of the most bothersome symptom (MBS) (time frame: From enrollment to the end of treatment at 4 or 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2025.